title: Guidelines for phototherapy of mycosis fungoides and Sézary syndrome: A consensus statement of the United States Cutaneous Lymphoma Consortium.
abstract: BACKGROUND
  Ultraviolet light (UVL) is a long established treatment for mycosis fungoides (MF) and Sézary syndrome (SS), subtypes of cutaneous T-cell lymphoma (CTCL). Treatments have traditionally included broadband, narrowband ultraviolet B light (UVB) and psoralen plus ultraviolet A light photochemotherapy (PUVA), but more recently, treatment options have expanded to include UVA1 and excimer laser. UVL is used either as monotherapy or as an adjuvant to systemic therapy, demonstrating efficacy in many cases that equal or surpass systemic medications. Despite its utility and duration of use, the current practice of using UVL guidelines for psoriasis to treat patients with MF/SS is problematic because the goals of prolonging survival and preventing disease progression are unique to CTCL compared to psoriasis.
  
  
  OBJECTIVE
  We sought to develop separate guidelines for phototherapy for MF/SS for both clinical practice and for clinical trials.
  
  
  METHODS
  Literature review and cutaneous lymphoma expert consensus group recommendations.
  
  
  RESULTS
  This paper reviews the published literature for UVB and UVA/PUVA in MF/SS and suggests practical standardized guidelines for their use.
  
  
  CONCLUSIONS
  New standardization of phototherapy.
  
  
  CONCLUSIONS
  These guidelines should allow the comparison of results with phototherapy in MF/SS across different stages of patients, centers, and in combination with other agents in practice and in clinical trials.
authors.affiliation: Departments of Dermatology and Medicine, Duke University Medical Center, Durham, North Carolina. Electronic address: elise.olsen@dm.duke.edu.
authors.forename: Elise A
authors.initials: EA
authors.lastname: Olsen
authors.affiliation: Department of Dermatology, Rabin Medical Center, Beilinson Hospital, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
authors.forename: Emilia
authors.initials: E
authors.lastname: Hodak
authors.affiliation: Department of Dermatology, University of Michigan, Ann Arbor, Michigan.
authors.forename: Thomas
authors.initials: T
authors.lastname: Anderson
authors.affiliation: Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts.
authors.forename: Joi B
authors.initials: JB
authors.lastname: Carter
authors.affiliation: Department of Dermatology, Henry Ford Hospital, Detroit, Michigan.
authors.forename: Marsha
authors.initials: M
authors.lastname: Henderson
authors.affiliation: Department of Dermatology, Case Western Reserve University, Cleveland, Ohio.
authors.forename: Kevin
authors.initials: K
authors.lastname: Cooper
authors.affiliation: Department of Dermatology, Henry Ford Hospital, Detroit, Michigan.
authors.forename: Henry W
authors.initials: HW
authors.lastname: Lim
mesh_terms: D005260:Female; D006801:Humans; D008297:Male; D009182:Mycosis Fungoides / Q000175:diagnosis / Q000628:therapy*; D011701:PUVA Therapy / Q000379:methods; D010789:Phototherapy / Q000379:methods*; D017410:Practice Guidelines as Topic; D011379:Prognosis; D018570:Risk Assessment; D012751:Sezary Syndrome / Q000175:diagnosis / Q000628:therapy*; D012878:Skin Neoplasms / Q000175:diagnosis / Q000628:therapy*; D012955:Societies, Medical; D016896:Treatment Outcome; D014467:Ultraviolet Therapy / Q000379:methods; D014481:United States
keywords: NB-UVB; PUVA; Sézary syndrome; UVL; cutaneous T-cell lymphoma; mycosis fungicides; phototherapy